El Instituto de Salud Carlos III utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como la recogida de estadísticas. Si continúa navegando, consideramos que acepta su uso. Para más información visite nuestra Política de Cookies.
Ver más información

We protect your health through science

Search Bar

Usa comillas para buscar una secuencia de palabras exacta. Ej: "Proyectos Financiados"

Investigation

Research Lines

Content with Investigacion Inmunidad Humoral y Vacunas frente al VIH .

Classical viral vaccines rely on the induction of neutralizing antibodies. In the case of infection by the human immunodeficiency virus (HIV), the viral spike has evolved to evade recognition by these antibodies. Despite these obstacles, certain monoclonal antibodies capable of neutralizing the majority of primary HIV-1 isolates have been successfully isolated and have demonstrated efficacy both in controlling viremia and in providing protection against infection in animal models. These are known as broadly neutralizing antibodies (bNAbs).


 

In order to identify the factors involved in the induction of these antibodies and to develop preventive strategies based on bNAb induction, we are pursuing the following research lines:

  1. Determination of factors associated with the induction of effective humoral responses in different scenarios: recent infection, chronic infection, co-infection with hepatitis C virus, reinfection, and pediatric infection, among others.
  2. Study of the effect of feminizing hormone therapy on the immune system of transgender women.
  3. Development of HIV-1 vaccine prototypes based on viral spike proteins incorporated into Virus-Like Particles (VLPs) from two sources:
    a) Selected from a library of randomly mutated spikes to enhance the accessibility of epitopes recognized by bNAbs.
    b) Derived from viruses present in individuals with broad neutralizing responses in recent infection.
  4. Isolation and characterization of new bNAbs against HIV-1 from individual B cells of individuals with an efficient neutralizing response. These antibodies could be used in both preventive and therapeutic strategies.
  5. Isolation of new monoclonal antibodies against other human pathogenic viruses, adapting the technology developed for HIV-1 antibody isolation, in collaboration with researchers from the National Center for Microbiology.
  6. Use of gene therapy vectors (Recombinant Adeno-Associated Viruses; rAAVs) to incorporate bNAbs and apply them in prophylactic and therapeutic strategies.

Research projects

Content with Investigacion Inmunidad Humoral y Vacunas frente al VIH .

Research Projects as Principal Investigators

Effect of Feminizing Hormone Therapy on the Immune Response in Transgender Women
Principal Investigator: Víctor Sánchez-Merino
Funding Agency: Intramural Health Strategic Action
Funding: €117,000
Participating Institutions: ISCIII, IRSICAIXA, 7 Infectious diseases units (Hospital General Universitario Gregorio Marañón (HGUGM-INF), Hospital Universitario La Paz (HULP), Hospital Universitario Infanta Leonor (HUIL), Hospital Fundación Jiménez Díaz (FJD), Fundación Universitario la Princesa (HUP), Hospital Universitario Ramón y Cajal (HURyC) y Hospital Universitario Doce de Octubre (HU12O), Centro Sandoval, 1 Gender Identity Unit, Facultad de psicología (UAM), Facultad de Geografía e Historia (UCM) and three ONGs
Duration: 01/01/2025- 31/12/2027
Project Reference: PI24CIII/00031

Design of Vaccine Prototypes based on HIV-1 Envelope presented on Virus-Like Particles and Nanodiscs
Principal Investigator: Eloísa Yuste Herranz
Funding agency: Knowledge Generation Projects. State Plan for Scientific and Technical Research and Innovation.
Funding: €125,000
Participating Institutions: ISCIII and University of UNSW (Sydney, Australia)
Duration: 01/09/24–31/12/28
Reference: Project PID2023-148729OB-100 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE.

 

Funding for Research Assistant Position. Project: New Approaches to Immunogen Design for the Induction of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) Based on Viral Envelope Proteins Presented on VLPs
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Youth Employment Plan (Community of Madrid)
Funding: Hiring of a senior graduate for 2 years
Participating Institutions: ISCIII
Duration: 01/04/2024 – 31/03/2026
Project Reference: SAL-GL-28125

Generation of an Adenovirus-Associated Vector for the Delivery of a Broadly Neutralizing Antibody (bNAb) Against HIV-1 That Does Not Induce Anti-Antibody Responses. Funding for Research Assistant Position. 
Principal Investigator: Víctor Sánchez Merino
Funding Agency: FUAX-Santander
Funding: €90,000
Participating Institutions: Universidad Alfonso X El Sabio and ISCIII
Duration: 01/04/2022 – 01/04/2025
Project Reference: 1.013.008

New Approaches to Immunogen Design for the Induction of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) Based on Viral Envelope Proteins Presented on Virus-Like Particles (VLPs). 
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Intramural Health Strategic Action
Funding: €77,000
Participating Institutions: Fraunhofer Institute (Germany) and ISCIII
Duration: 01/01/2021 – 30/06/2024
Project Reference: PI20CIII/00039

Development of Immunogens and Vaccination Strategies to Optimize the Induction of Broadly Neutralizing Antibodies (bNAbs) Against HIV-1.                                  
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Intramural Health Strategic Action
Funding: €117,000
Participating Institutions: Fraunhofer Institute (Germany) and ISCIII
Duration: 01/01/2018 – 31/12/2021
Personnel Hiring: One postdoctoral researcher for 3 years
Project Reference: PI17/00049

Isolation and Characterization of Broadly Neutralizing Antibodies Against HIV-1 from Recently Infected Patients.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Health Strategic Action (ISCIII)
Funding: €57,475
Participating Institutions: IDIBAPS, Fraunhofer Institute (Germany), and ISCIII
Duration: 01/01/2014 – 30/04/2017
Project Reference: PI13/01528

Development of an HIV Vaccine: Isolation and Characterization of New Broadly Neutralizing Antibodies.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Health Research Fund (ISCIII)
Funding: €116,765
Participating Institutions: IDIBAPS and ISCIII
Duration: 01/01/2010 – 31/12/2012
Project Reference: PI09/1459

Optimization of the HIV-1 Envelope Protein as an Immunogen.                            
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Spanish Foundation for AIDS Research and Prevention (FIPSE)
Funding: €141,845
Participating Institutions: IDIBAPS
Duration: 30/10/2008 – 31/08/2012
Personnel Hiring: One senior graduate for 3 years
Project Reference: 36780/08

Optimization of the HIV-1 Envelope Protein as an Immunogen.                           
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Ramón y Cajal Program (Ministry of Education and Science)
Funding: 5-year Ramón y Cajal Researcher contract + 3 years as I3
Participating Institutions: IDIBAPS
Duration: 2008 – 2016
Project Reference: RYC-2007-00788

R&D projects as part of the research team 

Determination of factors associated with protection against Human Immunodeficiency Virus type 1 Reinfection: Identification of protection correlates.
Principal Investigator: María Pernas Escario
Funding Agency: Gilead Sciences
Funding: €16,630
Participating Entities: Centro Sandoval and ISCIII
Duration: 01/01/2023 - 31/12/2023
Contract/Project File: GLD22/001144

EAVI2020: European AIDS Vaccine Initiative 2020
Principal Investigator: José Alcamí Pertejo
Funding Agency: Horizon 2020 (European Union; EU)
Funding: €403,829
Participating Entities: ISCIII and an EU consortium
Duration: 01/01/2015 - 30/04/2021
Contract/Project File: MPY1398/15

EHVA, European HIV Vaccine Alliance (EHVA): an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates.
Principal Investigator: Felipe García Alcaide
Funding Agency: Horizon 2020 (European Union; EU)
Funding: €1,000,000
Participating Entities: IDIBAPS and an EU consortium
Duration: 01/01/2018 - 31/12/2020
Contract/Project File: 681032

Grup de Recerca VIH/SIDA
Principal Investigator: José María Gatell
Funding Agency: AGAUR_SGR14 (Generalitat de Catalunya-projects)
Funding: €63,000
Participating Entities: IDIBAPS
Duration: 01/01/2014 - 30/04/2017
Contract/Project File: 214_SGR_706

SIDA Vaccine Research Project (HIVACAT)
Principal Investigator: José María Gatell
Funding Agency: MINECO (INNPACTO Program)
Funding: €288,740
Participating Entities: IDIBAPS and Irsicaixa
Duration: 01/01/2013 - 31/03/2020
Contract/Project File: PT-2012-0325-010000

Design, synthesis, and anti-HIV-1 study of peptide domains of GB virus B
Principal Investigator: Isabel Haro
Funding Agency: Foundation for AIDS Research and Prevention (FIPSE)
Funding: €33,000
Participating Entities: IQAC-CSIC and IDIBAPS
Duration: 09/03/2010 - 30/11/2014
Contract/Project File: 36-0735-09
 

Search Bar

Publications

Sort
Category

Detection of Rhabdovirus viral RNA in oropharyngeal swabs and ectoparasites of Spanish bats

Aznar C, Vazquez-Moron S, Martson D, Juste J, Ibáñez C, Berciano JM, Salsamendi E, Aihartza J, Banyard AC, McElhinney L, Fooks AR, Echevarria JE. Detection of Rhabdovirus viral RNA in oropharyngeal swabs and ectoparasites of Spanish bats. Journal of General Virology. 2013. 94: 69-75.

PUBMED DOI

Genomic non-coding regions reveal hidden patterns of mumps virus circulation in Spain, 2005 to 2015

Gavilán AM, Fernández-García A*, Rueda A, Castellanos A, Masa J, López-Perea N, Torres de Mier MV, de Ory F, Echevarría JE. Non-coding sequences reveal hidden patterns of mumps virus circulation in Spain, 2005 to 2015. Eurosurveillance,2018, 23(15): 1-8. *Corresponding author.

PUBMED DOI

First cases of European Bat Lyssavirus type 1 in Iberian serotine bats: implications for the molecular epidemiology of bat rabies in Europe.

Mingo-Casas P, Sandonís V, Obón E, Berciano JM, Vázquez-Morón S, Juste J, Echevarría JE. First cases of European Bat Lyssavirus type 1 in Iberian serotine bats: implications for the molecular epidemiology of bat rabies in Europe. Plos Neglected Tropical Diseases, 2018: 12(4): e0006290.

PUBMED DOI

Last cases of rubella and congenital rubella syndrome in Spain, 1997–2016: The success of a vaccination program

Seppälä EM, López-Perea N, Torres de Mier MV, Echevarría JE, Fernández García A, Masa-Calles J. Last cases of rubella and congenital rubella syndrome in Spain, 1997–2016: The success of a vaccination program. Vaccine, 2019, 37(1):169-175.

PUBMED DOI

Combination of Cefditoren and N-acetyl-l-Cysteine Shows a Synergistic Effect against Multidrug-Resistant Streptococcus pneumoniae Biofilms

Llamosí M, Sempere J, Coronel P, Gimeno M, Yuste J, Domenech M. Combination of Cefditoren and N-acetyl-l-Cysteine Shows a Synergistic Effect against Multidrug-Resistant Streptococcus pneumoniae Biofilms. Microbiol Spectr. 2022 Dec 21;10(6):e0341522

PUBMED DOI

Clearance of mixed biofilms of Streptococcus pneumoniae and methicillin-susceptible/resistant Staphylococcus aureus by antioxidants N-acetyl-L-cysteine and cysteamine

Sempere J, Llamosí M, Román F, Lago D, González-Camacho F, Pérez-García C, Yuste J, Domenech M. Clearance of mixed biofilms of Streptococcus pneumoniae and methicillin-susceptible/resistant Staphylococcus aureus by antioxidants N-acetyl-L-cysteine and cysteamine. Sci Rep. 2022 Apr 23;12(1):6668

PUBMED DOI

Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain

Sempere J, de Miguel S, González-Camacho F, Yuste J, Domenech M. Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain. Front Microbiol. 2020 Feb 27;11:309.

PUBMED DOI

Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract

Domenech M, Sempere J, de Miguel S, Yuste J. Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract. Front Immunol. 2018 Nov 20;9:2700. doi: 10.3389/fimmu.2018.02700. PMID: 30515172; PMCID: PMC6256034.

DOI

Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract

Corsini B, Díez-Martínez R, Aguinagalde L, González-Camacho F, García-Fernández E, Letrado P, García P, Yuste J. Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract. Antimicrob Agents Chemother. 2018 May 25;62(6):e02212-17. doi: 10.1128/AAC.02212-17. PMID: 29581113; PMCID: PMC5971604.

DOI

Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases

Richi P, Yuste J, Navío T, González-Hombrado L, Salido M, Thuissard-Vasallo I, Jiménez-Díaz A, Llorente J, Cebrián L, Lojo L, Steiner M, Cobo T, Martín MD, García-Castro M, Castro P, Muñoz-Fernández S. Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases. Vaccines. 2021 Feb 28;9(3):203. doi: 10.3390/vaccines9030203. PMID: 33671007; PMCID: PMC7997274.

DOI

Pleiotropic Effects of Cell Wall Amidase LytA on Streptococcus pneumoniae Sensitivity to the Host Immune Response

Ramos-Sevillano E, Urzainqui A, Campuzano S, Moscoso M, González-Camacho F, Domenech M, Rodríguez de Córdoba S, Sánchez-Madrid F, Brown JS, García E, Yuste J. Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response. Infect Immun. 2015 Feb;83(2):591-603. doi: 10.1128/IAI.02811-14. PMID: 25404032; PMCID: PMC4294232.

DOI

PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease

Ramos-Sevillano E, Urzainqui A, de Andrés B, González-Tajuelo R, Domenech M, González-Camacho F, Sánchez-Madrid F, Brown JS, García E, Yuste J. PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease. PLoS Pathog. 2016 Mar 14;12(3):e1005500. doi: 10.1371/journal.ppat.1005500. PMID: 26975045; PMCID: PMC4790886.

DOI

Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients

Martínez-González E; Brochado-Kith O; Gómez-Sanz A; et al; Fernández-Rodríguez A (AC). (9/9). 2020. Small RNA sequencing from plasma extracellular vesicles of HIV/HCV coinfected patients: a protocol comparison SCIENTIFIC REPORTS. 9. ISSN 2045-2322.

DOI

Relative telomere length impact on mortality of COVID-19: Sex differences

Virseda-Berdices A; Concostrina-Martinez L; Martínez-González O;et al; Fernández-Rodríguez A (AC). (14/14). 2022. Relative telomere length impact on mortality of COVID-19: Sex differences.Journal of medical virology. 95, pp.e28368. ISSN 0146-6615.

DOI

Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients

Martínez-Román P; López-Huertas MR; Crespo-Bermejo C; et al; Briz V (AC). (16/15). 2020. Hepatitis C virus influences HIV-1 viral splicing in coinfected patients JOURNAL OF CLINICAL MEDICINE. MDPI. ISSN 2077-0383.

DOI

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

Brochado-Kith; Martínez I; Berenguer J; et al; Fernández-Rodríguez A (AC); Resino S. (11/12). 2021. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. Journal of Biomedical Sciences. Springer Nature. 28-1.

DOI

OLFM4 polymorphisms predict septic shock survival after major surgery. Eur J Clin Invest.

Pérez-García F; Resino S; Gómez-Sánchez E; et al; Jiménez-Sousa MÁ (10/10). OLFM4 polymorphisms predict septic shock survival after major surgery. Eur J Clin Invest. 2021. 51(4):e13416. doi: 10.1111/eci.13416.

Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Buitrago MJ, Lopez JF, Grimalt JO, Cuenca-Estrella JM, Rodriguez-Tudela JL. Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother. 2006 Feb

Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Buitrago MJ, Lopez JF, Grimalt JO, Cuenca-Estrella JM, Rodriguez-Tudela JL. Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother. 2006 Feb;50(2):453-60. doi: 10.1128/AAC.50.2.453-460.2006. PMID: 16436696; PMCID: PMC1366924.

PUBMED

14. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008 Apr

Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008 Apr;52(4):1244-51. doi: 10.1128/AAC.00942-07. Epub 2008 Jan 22. PMID: 18212093; PMCID: PMC2292508.

PUBMED DOI

Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother. 2009 Oct

Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother. 2009 Oct;53(10):4514-7. doi: 10.1128/AAC.00585-09. Epub 2009 Jul 27. PMID: 19635955; PMCID: PMC2764190.

PUBMED DOI

Alcazar-Fuoli L, Mellado E, Cuenca-Estrella M, Sanglard D. Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med Mycol. 2011 Apr

Alcazar-Fuoli L, Mellado E, Cuenca-Estrella M, Sanglard D. Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med Mycol. 2011 Apr;49(3):276-84. doi: 10.3109/13693786.2010.512926. Epub 2010 Sep 10. PMID: 20831364.

PUBMED DOI

Alcazar-Fuoli L, Cuesta I, Rodriguez-Tudela JL, Cuenca-Estrella M, Sanglard D, Mellado E. Three-dimensional models of 14α-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction. Int J Antimicrob Agents. 2011 Nov

Alcazar-Fuoli L, Cuesta I, Rodriguez-Tudela JL, Cuenca-Estrella M, Sanglard D, Mellado E. Three-dimensional models of 14α-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction. Int J Antimicrob Agents. 2011 Nov;38(5):426-34. doi: 10.1016/j.ijantimicag.2011.06.005. Epub 2011 Aug 25. PMID: 21871783.

PUBMED DOI

Alcazar-Fuoli L, Mellado E. Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance.

Alcazar-Fuoli L, Mellado E. Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance. Front Microbiol. 2013 Jan 10;3:439. doi: 10.3389/fmicb.2012.00439. PMID: 23335918; PMCID: PMC3541703.

PUBMED DOI

Bernal-Martínez L, Alcazar Fuoli L, Miguel-Revilla B, Carvalho A, Cuétara Garcia MS, Garcia-Rodriguez J, Cunha C, Gómez-García de la Pedrosa E, Gomez-Lopez A. High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness. Antimicrob Agents Chemother. 2019 May 24

Bernal-Martínez L, Alcazar Fuoli L, Miguel-Revilla B, Carvalho A, Cuétara Garcia MS, Garcia-Rodriguez J, Cunha C, Gómez-García de la Pedrosa E, Gomez-Lopez A. High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness. Antimicrob Agents Chemother. 2019 May 24;63(6):e02399-18. doi: 10.1128/AAC.02399-18. PMID: 30910893; PMCID:PMC6535561.

PUBMED DOI

Lupiañez CB, Martínez-Bueno M, Sánchez-Maldonado JM, Badiola J, Cunha C, Springer J, Lackner M, Segura-Catena J, Canet LM, Alcazar-Fuoli L, López-Nevot MA, Fianchi L, Aguado JM, Pagano L, López-Fernández E, Alarcón-Riquelme M, Potenza L, Gonçalves SM, Luppi M, Moratalla L, Solano C, Sampedro A, González-Sierra P, Cuenca-Estrella M, Lagrou K, Maertens JA, Lass-Flörl C, Einsele H, Vazquez L; PCRAGA Study Group, Loeffler J, Ríos-Tamayo R, Carvalho A, Jurado M, Sainz J. Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis. Infect Immun. 2020 Mar 23

Lupiañez CB, Martínez-Bueno M, Sánchez-Maldonado JM, Badiola J, Cunha C, Springer J, Lackner M, Segura-Catena J, Canet LM, Alcazar-Fuoli L, López-Nevot MA, Fianchi L, Aguado JM, Pagano L, López-Fernández E, Alarcón-Riquelme M, Potenza L, Gonçalves SM, Luppi M, Moratalla L, Solano C, Sampedro A, González-Sierra P, Cuenca-Estrella M, Lagrou K, Maertens JA, Lass-Flörl C, Einsele H, Vazquez L; PCRAGA Study Group, Loeffler J, Ríos-Tamayo R, Carvalho A, Jurado M, Sainz J. Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis. Infect Immun. 2020 Mar 23;88(4):e00882-19. doi: 10.1128/IAI.00882-19. PMID: 31964743; PMCID: PMC7093133.

PUBMED DOI

Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality? Front Med (Laussane).

Ceballos FC; Ryan P; Blancas R; et al; Jiménez-Sousa MÁ (20/20). Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality? Front Med (Laussane). 2021; 8:718053. PMID: 34660629. doi: 10.3389/fmed.2021.718053.

T allele was linked to non-AIDS progression in ART-naïve HIV-infected patients: a retrospective study.

Jiménez-Sousa MA; Jiménez JL; Bellón JM; et al (1/10). CYP27B1 rs10877012 T allele was linked to non-AIDS progression in ART-naïve HIV-infected patients: a retrospective study. J Acquir Immune Defic Syndr 2020 ;85(5):659-664. doi: 10.1097/QAI.0000000000002485.

PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients

Salguero, Sergio; Brochado-Kith, Oscar; Verdices, Ana Virseda; et al; Jiménez-Sousa María A (‡, AC); Resino, Salvador (‡, AC). (12/12). 2023. PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study. Biomedicine & pharmacotherapy. 159, pp.114220. ISSN 1950-6007.

Relative telomere length impact on mortality of COVID-19: Sex differences.Journal of medical virology.

Virseda-Berdices, Ana; Concostrina-Martinez, Leyre; Martinez-Gonzalez, Oscar; et al; Fernandez-Rodriguez, Amanda (‡), Jiménez-Sousa María A (‡). (14/14). 2023. Relative telomere length impact on mortality of COVID-19: Sex differences.Journal of medical virology. 95-1, pp.e28368. ISSN 1096-9071.

Plasma miRNA profile at COVID-19 onset predicts severity status and mortality.

Fernandez-Pato, Asier; Virseda-Berdices, Ana; Resino, Salvador; et al; Jiménez-Sousa María A (‡, AC); Fernandez-Rodriguez, Amanda (‡). (20/20). 2022. Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. EMERGING MICROBES & INFECTIONS. 11(1):676-688. doi: 10.1080/22221751.2022.2038021.

Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis.The Journal of antimicrobial chemotherapy.

Virseda-Berdices, Ana; Brochado-Kith, Oscar; Diez, Cristina; et al; Jimenez-Sousa, Maria Angeles. (16/16). 2021. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis.The Journal of antimicrobial chemotherapy. 77(3):719-726. doi: 10.1093/jac/dkab444. ISSN 1460-2091.

Chronic pulmonary aspergillosis update: A year in review. Med Mycol. 2019 Apr 1

Barac A, Kosmidis C, Alastruey-Izquierdo A, Salzer HJF; CPAnet. Chronic pulmonary aspergillosis update: A year in review. Med Mycol. 2019 Apr 1;57(Supplement_2):S104-S109. doi: 10.1093/mmy/myy070. PMID: 30816975.

PUBMED DOI

Laursen CB, Davidsen JR, Van Acker L, Salzer HJF, Seidel D, Cornely OA, Hoenigl M, Alastruey-Izquierdo A, Hennequin C, Godet C, Barac A, Flick H, Munteanu O, Van Braeckel E. CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry. J Fungi (Basel). 2020 Jun

Laursen CB, Davidsen JR, Van Acker L, Salzer HJF, Seidel D, Cornely OA, Hoenigl M, Alastruey-Izquierdo A, Hennequin C, Godet C, Barac A, Flick H, Munteanu O, Van Braeckel E. CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry. J Fungi (Basel). 2020 Jun 29;6(3):E96. doi: 10.3390/jof6030096. PMID: 32610566.

PUBMED DOI

Project from GEMICOMED (SEIMC) and REIPI. Molecular identification and susceptibility testing of molds isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 study). Antimicrob Agents Chemother. 2018 Jun

Alastruey-Izquierdo A*, Alcazar-Fuoli L, Rivero-Menéndez O, Ayats J, Castro C, García-Rodríguez J, Goterris-Bonet L, Ibáñez-Martínez E, Linares-Sicilia MJ, Martin-Gomez MT, Martín-Mazuelos E, Pelaez T, Peman J, Rezusta A, Rojo S, Tejero R, Vicente Anza D, Viñuelas J, Zapico MS, Cuenca-Estrella M; members of the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI. Molecular identification and susceptibility testing of molds isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 study). Antimicrob Agents Chemother. 2018 Jun 25. doi: 10.1128/AAC.00358-18. PMID: 29941643.

PUBMED DOI

In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 May 1

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.* In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 May 1;74(5):1295-1299. doi: 10.1093/jac/dkz022. PMID: 30753499.

PUBMED DOI

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 Jun 1

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.* In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078. PMID: 30891600.

PUBMED DOI

Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in Aspergillus Species Received within a Surveillance Program on Antifungal Resistance in Spain. Antimicrob Agents Chemother. 2019 Aug 23

Rivero-Menendez O, Soto-Debran JC, Medina N, Lucio J, Mellado E, Alastruey-Izquierdo A*. Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in Aspergillus Species Received within a Surveillance Program on Antifungal Resistance in Spain. Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00865-19. PMID: 31285229.

PUBMED DOI

Clinical and Laboratory Development of Echinocandin Resistance in Candida glabrata: Molecular Characterization. Front Microbiol. 2019 Jul 11

Rivero-Menendez O, Navarro-Rodriguez P, Bernal-Martinez L, Martin-Cano G, Lopez-Perez L, Sanchez-Romero I, Perez-Ayala A, Capilla J, Zaragoza O, Alastruey-Izquierdo A*. Clinical and Laboratory Development of Echinocandin Resistance in Candida glabrata: Molecular Characterization. Front Microbiol. 2019 Jul 11;10:1585. doi: 10.3389/fmicb.2019.01585. PMID: 31354675.

PUBMED DOI

In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2020 Aug 28

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.* In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2020 Aug 28. doi: 10.1093/jac/dkaa351. PMID:32856079.

PUBMED DOI

Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes.

Martín-Vicente M*, Resino S#, Martínez I#*. Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes. J Biomed Sci. 2022 Feb 13;29(1):11. doi: 10.1186/s12929-022-00793-3. PMID: 35152905 (R; FI= 12.771; D1 Medicine, Research & Experimental; JCR 2021).

PUBMED

Content with Investigacion Inmunidad Humoral y Vacunas frente al VIH .

List of staff

Additional Information

Participation in research networks

Network Biomedical Research Center in Infectious Diseases
Participation: Member of the research team (Víctor Sánchez Merino); Coordinator of the "Preventive Vaccines against HIV-1" working group, HIV Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 2023 - Present
Code: CIBERINFEC, group CB21/13/00015

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the bNAbs Detection and Characterization Working Group, Vaccine Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2017-12/31/2021
Code: RETICS; RD16CIII/0002/0001

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the Vaccine Development Working Group, Immunopathogenesis Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2013-12/31/2017
Code: RETICS; RD12/0017

AIDS Research Network
Participation: Members of the research team (Víctor Sánchez Merino and Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 04/04/2008-12/31/2013
Code: RETICS; RD12/0017

Supervised doctoral theses

Development of immunogens and vaccination strategies to optimize the induction of broad-spectrum neutralizing antibodies against HIV-1. Student: Carolina Beltrán Pávez. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / ISCIII / Universitat de Barcelona. Defense date: 11/26/2018. Grade obtained: Excellent Cum Laude

Characterization of the neutralizing response of patients with recent HIV-1 infection and isolation of antibodies. Student: Amanda Fabra García. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 07/20/2017. Grade obtained: Excellent Cum Laude

Broadly neutralizing antibody responses against HIV-1: Characterization and design of new immunogens. Student: Carolina Barbosa Ferreira. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 02/25/2013. Qualification obtained: Excellent Cum Laude (European Doctorate)

Participation in research networks

Network Biomedical Research Center in Infectious Diseases
Participation: Member of the research team (Víctor Sánchez Merino); Coordinator of the "Preventive Vaccines against HIV-1" working group, HIV Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 2023 - Present
Code: CIBERINFEC, group CB21/13/00015

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the bNAbs Detection and Characterization Working Group, Vaccine Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2017-12/31/2021
Code: RETICS; RD16CIII/0002/0001

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the Vaccine Development Working Group, Immunopathogenesis Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2013-12/31/2017
Code: RETICS; RD12/0017

AIDS Research Network
Participation: Members of the research team (Víctor Sánchez Merino and Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 04/04/2008-12/31/2013
Code: RETICS; RD12/0017

Supervised doctoral theses

Development of immunogens and vaccination strategies to optimize the induction of broad-spectrum neutralizing antibodies against HIV-1. Student: Carolina Beltrán Pávez. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / ISCIII / Universitat de Barcelona. Defense date: 11/26/2018. Grade obtained: Excellent Cum Laude

Characterization of the neutralizing response of patients with recent HIV-1 infection and isolation of antibodies. Student: Amanda Fabra García. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 07/20/2017. Grade obtained: Excellent Cum Laude

Broadly neutralizing antibody responses against HIV-1: Characterization and design of new immunogens. Student: Carolina Barbosa Ferreira. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 02/25/2013. Qualification obtained: Excellent Cum Laude (European Doctorate)

Content with Investigacion Inmunidad Humoral y Vacunas frente al VIH .